Table 2.
Univariate and multivariate analysis of prognostic variables for cancer-specific survival in patients with ccRCC.
Variable | No. of patients | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
P | Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | ||
Age | |||||
>60 | 136 | ||||
< = 60 | 128 | 0.003 | 1.981(1.260–3.114) | 0.007 | 1.865(1.185–2.938) |
Sex | |||||
female | 92 | ||||
male | 172 | 0.536 | 1.149(0.741–1.781) | — | — |
Tumor stage | |||||
< = pT2 | 158 | ||||
> = pT3 | 106 | <0.001 | 3.881(2.419–6.226) | <0.001 | 2.766(1.706–4.482) |
Node stage | |||||
pN0 | 113 | ||||
pN1 | 7 | ||||
pNX | 144 | 0.290 | 0.889(0.715–1.105) | — | — |
Metastasis stage | |||||
pM0 | 196 | ||||
pM1 | 46 | ||||
pMX | 20 | <0.001 | 1.809(1.382–2.368) | <0.001 | 1.916(1.414–2.597) |
Fuhrman grade | |||||
< = G2 | 112 | ||||
> = G3 | 148 | ||||
GX | 2 | <0.001 | 3.031(1.874–4.900) | 0.001 | 2.589(1.464–4.580) |
CA9 methylation level | |||||
Low | 132 | ||||
High | 132 | 0.020 | 1.704(1.089–2.665) | 0.238 | 1.322(0.831–2.103) |
Abbreviation: No., Number.